198 related articles for article (PubMed ID: 17109182)
1. Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy.
Ugen KE; Nyland SB
Springer Semin Immunopathol; 2006 Nov; 28(3):281-7. PubMed ID: 17109182
[TBL] [Abstract][Full Text] [Related]
2. Addictive drugs and their relationship with infectious diseases.
Friedman H; Pross S; Klein TW
FEMS Immunol Med Microbiol; 2006 Aug; 47(3):330-42. PubMed ID: 16872369
[TBL] [Abstract][Full Text] [Related]
3. Will preventive HIV vaccine efficacy trials be possible with female injection drug users?
Meyers K; Metzger DS; McLellan AT; Navaline H; Sheon AR; Woody GE
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):577-85. PubMed ID: 8548338
[TBL] [Abstract][Full Text] [Related]
4. [Prevalence of HIV infection among drug users in Zuid-Limburg].
Wiessing LG; Houweling H; Meulders WA; Cerdá E; Jansen M; Sprenger MJ
Ned Tijdschr Geneeskd; 1995 Sep; 139(38):1936-40. PubMed ID: 7477534
[TBL] [Abstract][Full Text] [Related]
5. The feasibility of HIV vaccine efficacy trials among Russian injection drug users.
Beyrer C; Baral S; Shaboltas A; Dukhovlinova E; Masharsky A; Verevochkin S; Latkin C; Heimer R; Hoffman I; Kozlov A
Vaccine; 2007 Oct; 25(41):7014-6. PubMed ID: 17707960
[TBL] [Abstract][Full Text] [Related]
6. [HIV infection in intravenous drug addicts].
Boissonnas A; Wautelet V; Salmon D; Séréni D; Sicard D; Christoforov B
Rev Med Interne; 1993; 14(10):998. PubMed ID: 8009091
[TBL] [Abstract][Full Text] [Related]
7. Innate immune system damage in human immunodeficiency virus type 1 infection. Implications for acquired immunity and vaccine design.
Howie S; Ramage R; Hewson T
Am J Respir Crit Care Med; 2000 Oct; 162(4 Pt 2):S141-5. PubMed ID: 11029383
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
[TBL] [Abstract][Full Text] [Related]
9. A comparison of full-length glycoprotein 120 from incident HIV type 1 subtype E and B infections in Bangkok injecting drug users with prototype E and B strains that are components of a candidate vaccine.
Phan KO; Callahan ME; Vanichseni S; Hu DJ; Raktham S; Young N; Choopanya K; Mastro TD; Subbarao S
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1445-50. PubMed ID: 11018864
[TBL] [Abstract][Full Text] [Related]
10. Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand.
Pitisuttithum P; Choopanya K; Bussaratid V; Vanichseni S; van Griensven F; Phonrat B; Martin M; Vimutsunthorn E; Sangkum U; Kitayaporn D; Tappero JW; Heyward W; Francis D
J Med Assoc Thai; 2007 Nov; 90(11):2442-8. PubMed ID: 18181333
[TBL] [Abstract][Full Text] [Related]
11. Bacterial infections in drug users.
Gordon RJ; Lowy FD
N Engl J Med; 2005 Nov; 353(18):1945-54. PubMed ID: 16267325
[No Abstract] [Full Text] [Related]
12. Drug use and the risk of HIV infection amongst injection drug users participating in an HIV vaccine trial in Bangkok, 1999-2003.
Martin M; Vanichseni S; Suntharasamai P; Mock PA; van Griensven F; Pitisuttithum P; Tappero JW; Chiamwongpaet S; Sangkum U; Kitayaporn D; Gurwith M; Choopanya K;
Int J Drug Policy; 2010 Jul; 21(4):296-301. PubMed ID: 20079620
[TBL] [Abstract][Full Text] [Related]
13. Global HIV cohort studies among injecting drug users and future vaccine trials.
Woratanarat T
J Med Assoc Thai; 2006 Jul; 89(7):1064-79. PubMed ID: 16881444
[TBL] [Abstract][Full Text] [Related]
14. Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems.
Kumar S; Rao PS; Earla R; Kumar A
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):343-55. PubMed ID: 25539046
[TBL] [Abstract][Full Text] [Related]
15. Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression.
Casoli C; Pilotti E; Bertazzoni U
AIDS Rev; 2007; 9(3):140-9. PubMed ID: 17982939
[TBL] [Abstract][Full Text] [Related]
16. Substance use among women at risk for HIV infection.
Wambach KG; Byers JB; Harrison DF; Levine P; Imershein AW; Quadagno DM; Maddox K
J Drug Educ; 1992; 22(2):131-46. PubMed ID: 1625113
[TBL] [Abstract][Full Text] [Related]
17. [Adverse renal effects of legal and illicit drugs].
Orth SR
Ther Umsch; 2002 Mar; 59(3):122-30. PubMed ID: 11975400
[TBL] [Abstract][Full Text] [Related]
18. Current challenges for the creation of effective vaccines against drugs of abuse.
Moreno AY; Janda KD
Expert Rev Vaccines; 2011 Dec; 10(12):1637-9. PubMed ID: 22085165
[No Abstract] [Full Text] [Related]
19. Ethical Implications in Vaccine Pharmacotherapy for Treatment and Prevention of Drug of Abuse Dependence.
Carfora A; Cassandro P; Feola A; La Sala F; Petrella R; Borriello R
J Bioeth Inq; 2018 Mar; 15(1):45-55. PubMed ID: 29350320
[TBL] [Abstract][Full Text] [Related]
20. Preparations for AIDS vaccine trials. Retention, behavior change, and HIV-seroconversion among injecting drug users (IDUs) and sexual partners of IDUs.
Marmor M; Titus S; Wolfe H; Krasinski K; Maslansky R; Simberkoff M; Beatrice S; Nichols S; Des Jarlais DC
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S207-13. PubMed ID: 7865302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
